Big Pharma Has Mad Love For These 2 Biotechs
These companies' collaborations with bigger businesses validates their science -- and paves the way for future revenues and profits.
Regenxbio
RGNX
RGNX
$38.53
$0.83
2.2%
BATS BZX Real Time Price as of October 16, 2019, 3:13 p.m. EDT
View Interactive RGNX Charts
REGENXBIO INC COM USD0.0001
News & Analysis: Regenxbio
3 Blindness-Fighting Biotech Stocks That Could Surge This Week
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
3 Top Biotech Stocks to Buy Right Now
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
Regenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
RGNX earnings call for the period ending June 30, 2019.
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Regenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
Regenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
RGNX earnings call for the period ending December 31, 2018.
Here's Why Gene Therapy Stocks Are Soaring Today
Roche acquired Spark Therapeutics for a cool $4.8 billion, which sent peers soaring.
